AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01400646
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).
Trial: NCT01400646
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).
Trial: NCT01400646
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)
Trial: NCT01400646
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).
Trial: NCT01400646
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).
Trial: NCT03016611
Drug: Chewing Ticagrelor LD
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 mg Chewing Ticagrelor
Trial: NCT03016611
Drug: Chewing Prasugrel LD
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60 mg Chewing Prasugrel
Trial: NCT01794780
Drug: LABA based treatment: indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LABA based treatment: indacaterol
Trial: NCT01794780
Drug: LAMA based treatment: tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAMA based treatment: tiotropium
Trial: NCT01794780
Drug: LABA/ICS based treatment: salmeterol/fluticasone
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: LABA/ICS based treatment: salmeterol/fluticasone
Trial: NCT01794780
Drug: LABA/ICS based treatment: budesonide/formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: LABA/ICS based treatment: budesonide/formoterol
Trial: NCT00444015
Drug: Erlotinib in combination with Dasatinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 Cycles @ 28 Days
Trial: NCT03607227
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active substance. Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
Trial: NCT03607227
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo. Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as the active substances.
Trial: NCT00302692
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00302692
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04556071
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib will be administered orally once a day continuously throughout each 21-days cycle. The initial dose will be based on the participant's basal body weight or platelet count. Participants with basal body weight≥77 kg and basal platelet count of≥150,000/microliter (μL) will take 300 mg daily. While participants with basal body weight\<77 kg and/or basal platelet count \<150,000/μL will take 200 mg daily.
Trial: NCT01078753
Drug: Desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.
Trial: NCT01874483
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004, dose 2
Trial: NCT01874483
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004, dose 4
Trial: NCT01874483
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004, dose 5
Trial: NCT01874483
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004, dose 6
Trial: NCT01874483
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004, dose 7
Trial: NCT01874483
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004, dose 1
Trial: NCT01874483
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004, dose 3
Trial: NCT03364218
Drug: N-Acetyl Cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized N-Acetyl Cysteine administered every 12 hours
Trial: NCT00462423
Drug: Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avastin 10 mg/kg IV every 2 weeks (without rest period).
Trial: NCT00462423
Drug: Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abraxane 150 mg/m2 IV weekly for 3 weeks of a 28-day cycle.
Trial: NCT01772134
Drug: Umeclidinium bromide 62.5mcg
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalation Powder, LAMA 62.5mcg
Trial: NCT01772134
Drug: Umeclidinium bromide 125mcg
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalation Powder, LAMA 125mcg
Trial: NCT01772134
Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhalation Powder, ICS/LABA
Trial: NCT03486314
Drug: Pevonedistat
RxNorm normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat intravenous infusion.
Trial: NCT03486314
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin capsules.
Trial: NCT03486314
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel intravenous infusion.
Trial: NCT03486314
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin intravenous infusion.
Trial: NCT03486314
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel intravenous infusion.
Trial: NCT02721862
Drug: Ursodeoxycholic Acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid, is FDA approved for the reduction in gallstone formation in obese patients undergoing rapid weight loss.Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder.
Trial: NCT01440101
Drug: Natalizumab (BG00002)
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00763893
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/day if \< weight 50 kg 100 mg/day if weight \> 50 kg
Trial: NCT00636818
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug is administered once daily in the morning. This study is designed with 4-step titration. At Day 1, study drug is started from 40 mg/day, and is increased to 80 mg/day on Day 7, 105 mg/day on Day 14, and 120 mg/day on Day 28. Total administration period is 8 weeks. The dosage is adjusted according to investigator's decision based on safety and tolerability.
Trial: NCT02485717
Drug: spinosad topical suspension, 0.9%
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
Trial: NCT02279511
Drug: ADENOSINE TRIPHOSPHATE
RxNorm normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
Trial: NCT01254344
Drug: ertapenem sodium
RxNorm normalized name: Ertapenem Sodium
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Trial: NCT01254344
Drug: ceftriaxone sodium
RxNorm normalized name: Ceftriaxone Sodium
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Trial: NCT01254344
Drug: placebo to metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Trial: NCT01254344
Drug: metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Trial: NCT00789126
Drug: VX-509
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04355286
Drug: Bemotrizinol
RxNorm normalized name: bemotrizinol
DrugBank: Bemotrizinol (DB11206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Market-image topical sunscreen formulation containing BEMT (6%)
Trial: NCT01851096
Drug: SNX-5422
RxNorm normalized name: SNX-5422
DrugBank: SNX-5422 (DB06070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).
Trial: NCT03280212
Drug: Tranexamic Acid 500 MG
RxNorm normalized name: tranexamic acid 500 MG
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid 500mg oral tablets.
Trial: NCT01982630
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00786240
Drug: Fesoterodine
RxNorm normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)
Trial: NCT00786240
Drug: Fesoterodine
RxNorm normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)
Trial: NCT04396587
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone(20μg/kg)was administered before anesthesia induction.
Trial: NCT04396587
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone(60μg/kg) was administered before anesthesia induction.
Trial: NCT00160927
Drug: sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04556071
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The dose of Bevacizumab will be 15 mg/kg that administered via a 30-minute intravenous infusion on day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death.
Trial: NCT03624959
Drug: Ozanimod
RxNorm normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ozanimod
Trial: NCT03624959
Drug: Gemfibrozil
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil
Trial: NCT03624959
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole
Trial: NCT03624959
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin
Trial: NCT04439786
Drug: lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
Trial: NCT00274430
Drug: dexamethasone 8 mg bid
RxNorm normalized name: dexamethasone 8 MG
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00274430
Drug: tadalafil 10mg bid
RxNorm normalized name: tadalafil 10 MG
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03310125
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over-encapsulated 0.5mg tablet twice daily
Trial: NCT01907685
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for infusion~Route of administration: Intravenous
Trial: NCT00303810
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00303810
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00303810
Drug: etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00303810
Drug: lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00303810
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00303810
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02885181
Drug: GS-9876
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One tablet administered orally once daily
Trial: NCT01259466
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
Trial: NCT00448461
Drug: bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparison between heparin and bivalirudin
Trial: NCT02725502
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with continuous glucose monitoring system (CGMS). Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
Trial: NCT02885181
Drug: Filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Two tablets administered orally once daily
Trial: NCT02885181
Drug: Filgotinib placebo
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Two tablets administered orally once daily
Trial: NCT02280811
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days.
Trial: NCT02280811
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Trial: NCT00443521
Drug: Triamcinolone Acetonide 4 mg intravitreal injection
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01374698
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg
Trial: NCT00820105
Drug: ADX10059
RxNorm normalized name: ADX10059
DrugBank: ADX10059 (DB05070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00820105
Drug: ADX10059
RxNorm normalized name: ADX10059
DrugBank: ADX10059 (DB05070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00820105
Drug: ADX10059 Matching Placebo
DrugBank: ADX10059 (DB05070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01201499
Drug: Intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a single dose of intrathecal morphine (ITM, 4 µcg/kg, or \~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.
Trial: NCT00175981
Drug: sildenafil, fluvoxamine
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00752986
Drug: ZD6474 (Vandetanib at the dose of 100 mg)
RxNorm normalized name: vandetanib 100 MG
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Trial: NCT00752986
Drug: Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)
RxNorm normalized name: vandetanib 100 MG
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Trial: NCT00752986
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.
Trial: NCT00752986
Drug: ZD6474 (Vandetanib at the dose of 300 mg)
RxNorm normalized name: vandetanib 300 MG
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first.
Trial: NCT00752986
Drug: Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)
RxNorm normalized name: vandetanib 300 MG
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Trial: NCT03949673
Drug: Fasinumab
RxNorm normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Trial: NCT03414879
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: While in the semi-setting position, patients will receive nebulization with ketamine 3 mg/kg to be completed with normal saline solution to reach a volume of 6 ml (K group; n=30) for 15 minutes before commencing the awake fiberoptic intubation..
Trial: NCT03414879
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: While in the semi-setting position, patients will receive nebulization with lidocaine 4% 6 ml (L group; n=30) for 15 minutes before commencing the awake fiberoptic intubation
Trial: NCT00033735
Drug: Irofulven
RxNorm normalized name: Irofulven
DrugBank: Irofulven (DB05786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irofulven will be given at 0.55 mg/kg per infusion on Day 1 and and Day 15 every 28 days as a 30 minute iv infusion.
Trial: NCT04244825
Drug: BLD-2660
RxNorm normalized name: BLD-0409
DrugBank: Cudetaxestat (DB18203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLD-2660 - 150 mg capsules '00' size (PO) BID